Stock Analiz

Aclaris Therapeutics, Inc. (ACRS) stock forecast and price target

Price $3.92 · data as of November 13, 2026

12-month price target

Average target$10.36
Upside / downside+164.4%
Analysts11
ConsensusStrong buy
Low $4.00Average $10.36High $16.00

Gold marker: average target · white marker: today’s price ($3.92)

Analyst ratings

Strong buy 1Buy 10Hold 1Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.60−12.6%$6M
Next fiscal year
ends December 31, 2027
$-0.70−17.6%$5M
Next quarter
ends December 31, 2026
$-0.17−5.7%$1M
Quarter after
ends March 31, 2027
$-0.20−33.3%$1M

Consensus of the analysts covering Aclaris Therapeutics, updated daily. In the last 30 days 6 estimates were raised and 0 lowered.

Frequently asked questions

What is the Aclaris Therapeutics stock price target?

The average 12-month target from 11 analysts is $10.36, 164.4% above the current price of $3.92 Targets range from $4.00 to $16.00.

Is Aclaris Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 10 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Aclaris Therapeutics expected to earn?

Analysts expect EPS of $-0.60 for the fiscal year ending December 31, 2026 and $-0.70 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.